Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles

Core Insights - Wall Street analysts have turned bullish on Hims & Hers (HIMS), Teladoc Health (TDOC), and Alector (ALEC) due to strategic partnerships that have reshaped their risk profiles [1][2] Company Summaries Hims & Hers Health (HIMS) - HIMS stock surged 34.47% to $22.16 after resolving a lawsuit with Novo Nordisk through a distribution partnership, with price targets set between $23 and $28 by analysts [1] - BofA upgraded HIMS from Underperform to Neutral, raising the price target from $12.50 to $23, citing the removal of legal risks [1] - Deutsche Bank maintained a Hold rating but increased the target to $28, highlighting the strategic shift away from compounded semaglutide [1][2] Teladoc Health (TDOC) - TDOC's stock is currently priced at $5.30, with Deutsche Bank upgrading it from Hold to Buy and setting a price target of $11, indicating substantial upside potential [1] - The upgrade is based on compelling valuation, a credible turnaround plan for the BetterHelp segment, and stable revenue from the Integrated Care segment, which grew 2% in Q3 2025 [1][2] - The company reported Q3 2025 revenue of $626.44 million, missing consensus estimates, with BetterHelp revenue declining 8% [1] Alector (ALEC) - ALEC's stock rose 40.38% year-to-date to $2.19, with BTIG upgrading it from Neutral to Buy and setting a price target of $6 [1] - The upgrade reflects confidence in Alector's pivot to its Alector Brain Carrier (ABC) platform following a setback in a frontotemporal dementia trial [1] - Alector reported Q4 2025 revenue of $6.24 million, significantly beating the consensus estimate of $2.11 million, and holds $256 million in cash to fund operations through 2027 [1][2]